[The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML].
OBJECTIVE
To compare the efficacy of high-dose cytarabine (HD-Ara-C) based chemotherapy for post-remission treatment in patients with t(8;21) (q22;q22) AML-M2 and those with normal karyotype AML-M2.


METHODS
AML-M2 patients were grouped into with (21 cases) or without (23 cases) t(8;21) (q22;q22) karyotype groups. After achieved remission by induction therapy, all patients received four cycles of HD-Ara-C (3 mg/m2 per 12 hours by three-hour infusion day 1 to day 3) with either mitoxantrone (7 mg m(-2) d(-1)) or aclarubicin (30 mg m(-2) d(-1)) or etoposide (70 mg m(-2) d(-1)) for 3d as post-remission treatment.


RESULTS
Relapse rate in the t(8;21) and the normal karyotype groups was 29% and 57% respectively (P<0.05); 3 year disease-free survival (DFS) rate was 71% and 43% respectively (P < 0.05). and 3 year over-all survival (OS) rate was 76% and 65% respectively (P >0.05).


CONCLUSIONS
Four cycles of high-dose cytarabine based combination chemotherapy as post-remission treatment improves long-term disease-free survival in patients with t(8;21) (q22;q22) AML-M2.
Li
Hong-Yi
HY
Department of Hematology, Henan Cancer Hospital, Henan Institute of Hematology, Zhengzhou 450008, China.
Yue
Han
H
Wei
Xu-Dong
XD
Zhu
Xing-Hu
XH
Zhang
Yan-Li
YL
Zhang
Li-Na
LN
Liu
Yan-Yan
YY
Wang
Ping
P
Fang
Bai-Jun
BJ
Li
Yu-Fu
YF
Song
Yong-Ping
YP
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
D003561:Cytarabine